HCA-7 Colony 29

02091238

• UNSPSC-Code: 41106514

Eigenschaften

• Biologische Quelle: human colon
• Wachstumsmodus: Adherent
• Karyotyp: Near Diploid
• Morphologie: Epithelial
• Produkte: Expresses Cox-2
• Rezeptoren: EGF. Parent HCA-7 cell line: wildtype APC. Known mutations:Parent HCA-7 cell line: RER phenotype, p53
• Methode(n): cell culture | mammalian: suitable
• Relevante Krankheit(en): cancer
• Versandbedingung: dry ice
• Lagertemp.: −196°C

Beschreibung

Ursprung der Zelllinie

Human Colon Carcinoma (subpopulation isolated from the HCA-7 cell line)

Beschreibung der Zelllinie

The human colon cancer cell line, HCA-7 Colony 29 expresses Cox-2. An interesting feature of this cell line is that it forms polarised epithelial sheets which allows examination of the trafficking and release of biomolecules in vitro. Cyclooxygenases (COXs) are key enzymes in the conversion of arachidonic acid to prostaglandins and other eicosanoids. It has been found that colonic polyps and cancers overexpress Cox-2 and that the inhibition of this enzyme by nonsteroidal anti-inflammatory drugs decreases the risk of colonic neoplasia. This cell line is useful for studying the role of Cox-2 in cancer cell biology and the investigation of colorectal epithelial cell polarity. Imperial College Innovations has stated that this cell line is not to be supplied to commercial organisations.

DNA-Profil

STR-PCR Data: Amelogenin: X
CSF1PO: 11,14
D13S317: 9
D16S539: 10,11
D5S818: 8,12
D7S820: 11,12
THO1: 6,7
TPOX: 8,10
vWA: 14,16

Nährmedium

DMEM + 10% FBS + 2mM L-Glutamine + 110mg/L Sodium Pyruvate (NaP).

Subkultur-Routine

Split sub-confluent cultures (70-80%) 1:5 to 1:10 i.e. seeding at 1-2x10,000 cells/cm² using 0.05% trypsin/EDTA; 5% CO₂; 37°C.

Sonstige Hinweise

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

Haftungsausschluss

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.